+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of finerenone compared to a placebo in patients hospitalized with acute decompensated heart failure who have mildly reduced or preserved left ventricular ejection fraction. This international, randomized, double-blind, placebo-controlled Phase 3 trial aims to study how finerenone affects morbidity and mortality in these patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study is event-driven and will monitor patients for up to approximately 30 months. It includes ongoing evaluation of heart failure events, cardiovascular death, and adverse events related to the study drug. Both groups will be observed throughout this period to compare outcomes. During the trial, participants will undergo regular assessments including monitoring for heart failure events, cardiovascular death, and serious adverse events. The study will also measure changes in symptom scores using the Kansas City Cardiomyopathy Questionnaire at 6 months. Safety and tolerability will be closely tracked, including adverse events leading to discontinuation of the study drug. Participants will be followed for up to 30 months to assess long-term effects.

Age: 18Years +All GendersPhase 3
356 locations
S

Actively Recruiting

Researchers are evaluating finerenone compared to a placebo to assess the effectiveness and safety of treatment in patients with heart failure and reduced ejection fraction HFrEF who cannot tolerate or are not eligible for steroidal mineralocorticoid receptor antagonists sMRA. This international study is a randomized, double-blind, placebo-controlled trial focused on this specific group of heart failure patients. Participants will be randomly assigned to receive either oral finerenone or a matching placebo. The study uses a parallel design and treatment will be monitored for up to about 30 months. During this time, researchers will track cardiovascular events, heart failure events, and any serious or adverse events leading to discontinuation of the study drug. Throughout the study, participants will undergo regular assessments including symptom questionnaires and monitoring for cardiovascular outcomes and safety. The main outcomes include the time to the first cardiovascular death or heart failure event and the number of serious adverse events. The study also tracks changes in symptom scores over six months and overall survival. Participants will be followed closely during treatment and after to understand both efficacy and safety.

Age: 18Years +All GendersPhase 3
176 locations
E

Actively Recruiting

Researchers are investigating adults in Sri Lanka with heart failure with reduced ejection fraction HFrEF to assess how an HFrEF polypill strategy affects the combined rate of cardiovascular death and repeated heart failure hospitalizations compared to usual care. The study evaluates this over at least 12 months of follow-up and includes secondary outcomes such as mortality rates, heart function changes via echocardiogram, and quality of life measures. Participants will be randomly assigned to two groups one receives usual care with guideline-directed medications dispensed at no charge when available, while the other receives a combined polypill containing bisoprolol, losartan, eplerenone, and dapagliflozin in three possible dose strengths. The polypill dose will be adjusted during scheduled visits to reach the highest tolerated dose, aiming for the strongest dose by study end. During the study, participants undergo regular visits at 1, 3, 6, 9, and 12 months and every 3 months thereafter, averaging 18 months total. Researchers will monitor heart function, biomarker levels, quality of life questionnaires, medication adherence, and safety outcomes including adverse events and laboratory measures like potassium and creatinine levels. The study includes detailed assessments to evaluate treatment persistence, dose optimization, and overall health impact over time.

Age: 18Years +All GendersPhase 3
12 locations